Status:
RECRUITING
PROOF OF CONCEPT STUDY ON THE EFFICACY OF INHALATORY TARGETED IMATINIB NANOFORMULATIONS IN PULMONARY HYPERTENSION AND POST-INFLAMMATORY FIBROSIS.
Lead Sponsor:
Fondazione IRCCS Policlinico San Matteo di Pavia
Conditions:
Pulmonary Arterial Hypertension (PAH)
Lung Fibrosis Interstitial
Eligibility:
All Genders
18+ years
Brief Summary
The PROMPTLY study is a proof-of-concept research project evaluating the efficacy of XHALIP, an innovative inhalable formulation of Imatinib, in treating pulmonary arterial hypertension (PAH) and post...
Eligibility Criteria
Inclusion
- Patients aged ≥ 18 years diagnosed with fibrosing lung disease, obliterative bronchiolitis, or PAH, who are candidates for or have undergone lung transplantation.
- Obtaining informed consent for all patients enrolled prospectively and all those enrolled retrospectively at their first clinical occurrence at our center.
Exclusion
- Suspected or confirmed diagnosis of pulmonary neoplastic disease.
Key Trial Info
Start Date :
December 4 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 4 2026
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT06917196
Start Date
December 4 2023
End Date
June 4 2026
Last Update
April 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione IRCCS Policlinico San Matteo
Pavia, Pavia, Italy, 27100